0HF3.L
Cencora
Q2 2025 Report
Cencora (0HF3.L) Q2 2025 Financial Results: Strong Net Income Growth Amid Cost Challenges...
Read full report
Executive Summary
In Q3 2025, Cencora (0HF3.L) reported a strong revenue of $80.66 billion, reflecting an 8.65% year-over-year growth. Despite facing pressures in gross profit margins, the firm managed to deliver net income of $687.4 million, a 42.18% increase YoY, indicating solid operational execution amidst challenging market conditions. Management highlighted their commitment to optimizing operational efficiencies and expanding their market share in both domestic and international markets, anticipating that their business positioning will yield favorable outcomes moving into the next quarters.
Notably, the company maintained a strong liquid position with $2.23 billion in cash, though operational cash flow turned negative primarily due to working capital adjustments. Investor confidence is buoyed by Cencora's strategic investments in technology and clinical services that enable comprehensive healthcare solutions aligned with market demands.
Key Performance Indicators
Revenue
80.66B
QoQ: 6.90% | YoY:8.65%
Gross Profit
2.91B
3.60% margin
QoQ: -4.99% | YoY:39.32%
Operating Income
867.65M
QoQ: -16.26% | YoY:23.36%
Net Income
687.40M
QoQ: -4.24% | YoY:42.18%
EPS
3.55
QoQ: -4.05% | YoY:45.49%
Revenue Trend
Margin Analysis
Key Insights
- **Revenue**: $80.66 billion, up 8.65% YoY and 6.90% QoQ.
- **Gross Profit**: $2.91 billion, up 39.32% YoY but down 4.99% QoQ, indicating slight pressure on margins.
- **Operating Income**: $867.65 million, representing a 23.36% YoY growth, however down from last quarter due to increased operating expenses.
- **Net Income**: $687.4 million, a 42.18% increase YoY and 4.24% decrease QoQ, highlighting strong year-long operational effectiveness.
- **EPS**: $3.55, reflecting a 45.49% YoY increase.